Michael B. Atkins, MD, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, discusses the efficacy of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF-mutated melanoma.
Archive | Video Reports
Dr. Atkins on the Efficacy of Dabrafenib/Trametinib in BRAF-Mutated Melanoma
Posted in Melanoma News, Health Professionals, Video Reports
Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments
Jason Luke, MD, FACP of the UPMC Hillman Cancer Center spoke with CancerNetwork about the latest developments regarding melanocytes, dysregulated pathways and melanoma at the SMR Conference.
Posted in Melanoma News, Health Professionals, Video Reports
Dr. Luke on the Importance of BRAF in Melanoma
Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the importance of BRAF in melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma
Geoffrey T. Gibney, MD, co-leader, Melanoma Disease Group and a member of the Developmental Therapeutics (Phase I) program at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network, MedStar Georgetown University Hospital, discusses selecting between BRAF inhibitor regimens in melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
